Second-line chemotherapy with bleomycin, methotrexate, and vinorelbine (BMV) for patients with squamous cell carcinoma of the head, neck and esophagus (SCC-HN&E) pretreated with a cisplatin-containing regimen: a phase II study
Articolo
Data di Pubblicazione:
2003
Citazione:
Second-line chemotherapy with bleomycin, methotrexate, and vinorelbine (BMV) for patients with squamous cell carcinoma of the head, neck and esophagus (SCC-HN&E) pretreated with a cisplatin-containing regimen: a phase II study / M. Moroni, L. Giannetta, G. Gelosa, S. Secondino, G. Chillura, E. Colombo, S. Siena. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1120-009X. - 15:4(2003 Aug), pp. 394-399.
Abstract:
We evaluated the toxicity and activity of bleomycin, methotrexate and vinorelbine (BMV) combination chemotherapy in cisplatin-pretreated patients with squamous cell carcinoma of the head, neck and esophagus (SCC-HN&E) with the aim of identifying a second-line therapy combination and schedule that might offer an improved therapeutic index. BMV (bleomycin 15 I.U., total dose, methotrexate 30 mg/m2, and vinorelbine 30 mg/m2) was administered intravenously every 2 weeks until disease progression, to 26 consecutive patients. Clinical and CT-scan evaluations revealed 7 partial responses (PR) 127%, 95% confidence interval: 9.6%-44.4%], and 13 patients with stable disease (SD) [50%]. The mean progression-free survival for patients who achieved a PR or SD was 6.47 months (range 4-13 months), with 75% of these patients experiencing partial relief of symptoms, mainly pain and dysphagia. BMV, administered second-line in an outpatient setting, has activity similar to that of the taxanes, but with a more acceptable toxicity profile including an absence of alopecia.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
bleomycin; head and neck; methotrexate; platinum-resistant; second-line; squamous cell carcinoma; vinorelbine
Elenco autori:
M. Moroni, L. Giannetta, G. Gelosa, S. Secondino, G. Chillura, E. Colombo, S. Siena
Link alla scheda completa: